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As anacute neurotoxicity, high dose5-fluorouracil (5-FU)-induced encephalopathy iswell-known,
but encephalopathy associated with lower dose is rarely reported. Here, we report a case of a
male with anal cancer who was treated with 5-FU 1000 mg/m2, continuous infusion for 5 days
q4 weeks. At the second and the fourth cycles of chemotherapy, sudden confusion, cognitive
dysfunction and disorientation occurred during 5-FU infusion. They were accompanied by
hyperammonemia in the absence of focal neurological deficits or structural abnormalities.
These symptoms completely disappeared and the serum ammonia level returned to normal
after discontinuation of 5-FU and conservative care. In order to investigate a possible deficit
of dihydropyrimidine dehydrogenase (DPD), we checked its mRNA level before and after treat-
ment using real-time PCR. The patient’s pre-treatment level was 80% compared with reference
group, and it was elevated up to 187% of initial after 5-FU treatment, implying that that his
encephalopathymay be 5-FU catabolite type rather thanDPDdeficiency. In conclusion,we report
that encephalopathy can develop even with the dose of 5-FU lower than ever reported, and it
should be considered as a differential diagnosis for proper management.
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INTRODUCTION
Neurotoxicity is an uncommon side effect of 5-fluorouracil
(5-FU) treatment (1,2). Two types of well-recognized neuro-
toxicity have been described, namely acute and chronic. Acute
neurotoxicity, which manifests as a diffuse encephalopathy or
a cerebellar syndrome, is known as dose-related and generally
self-limiting. Delayed neurotoxicity, which appears with a few
months interval, has been reported when 5-FU was given with
levamisole. This form of subacute multifocal leukoencephalo-
pathy is immune-mediated and responds to corticosteroids
(3,4). Most cases of 5-FU induced encephalopathy are asso-
ciated with infusion of high-dose 5-FU (>2200 mg/m2 every
week). However, encephalopathy associated with lower dose of
5-FU has been rarely reported. Here we report a case of tran-
sient encephalopathy related to intermediate-dose 5-FU infu-
sion (1000 mg/m2, continuous infusion for 5 days q4 weeks) in
a patient with anal cancer. Additionally, in order to investigate
a possible defect of dihydropyrimidine dehydrogenase (DPD),
we checked its mRNA level in the patient before and after
treatment using real-time PCR.
CASE REPORT
A 68-year-old Korean male, who had been diagnosed of anal
cancer with bladder and prostate invasion, was admitted to
the hospital for a course of chemotherapy. He had no history
of chronic alcohol or benzodiazepine addiction or any other
significant medical history. His initial liver function test and
abdomen-pelvis CT scan showed no abnormal findings other
than locally infiltrated anal mass. Combination chemotherapy
was planned with infusion of 5-FU (1000 mg/m2, continuous
infusion, D1–5) and cisplatin (70 mg/m2, 2 h-infusion, D1),
which was to be repeated every 4 weeks (Table 1). Other
medications included dexamethasone 10 mg i.v. before
chemotherapy, and two doses of ondansetrone.
He finished the first cycle of chemotherapy without signs
of remarkable toxicity. However, in the second cycle, sudden
mental change emerged on the fifth day of 5-FU infusion (109 h
from infusion, total dose infused was 4500 mg/m2). The blood
pressure checked was 120/80 mmHg, the pulse rate 80/min,
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and the respiratory rate 14/min. Neurological examination
revealed cognitive abnormalities in the form of confusion
and disorientation to place and time. The patient had impaired
memory, calculation, judgment and naming difficulty. Deep
tendon jerks were all 2+ and symmetric. CT and MRI scan
of the brain showed no evidence of metastasis or stroke.
Laboratory examination showed elevated ammonia level to
354 mg/dl (0–64) and slightly elevated total bilirubin level
to 1.6 mg/dl (0.2–1.2). Other laboratory findings, such as
complete blood count, serum electrolytes including sodium,
potassium, calcium and aminotransferases level, were all in
the normal range (Table 2). Serum levels of glucose and
creatinine were within normal range. Blood and urine culture
were negative. 5-FU infusion was stopped immediately and
i.v. hydration along with lactulose enema were performed.
Patient’s mental status was recovered completely 24 h after
the discontinuation of 5-FU and the serum ammonia level
fell down to 58 mg/dl.
Assuming that his neurotoxicity was drug-related, we
decided to reduce the dose of cisplatin to 60 mg/m2 without
modifying 5-FU from the next cycle. On the admission for
third cycle of chemotherapy, his pre-treatment serum ammonia
level was 63 mg/dl. Although the level was slightly increased
to 120 mg/dl in the course of 5-FU infusion, neurotoxicity was
not documented with him. However, at the fourth cycle,
another attack of neurotixicity developed on the second day
of 5-FU infusion (37 h from infusion, total dose infused was
1500 mg/m2). Neurological symptoms and signs were the
same as those at the second cycle. Serum ammonia level
was elevated up to 555 mg/dl without affecting other laboratory
and radiological findings. After hydration and enema, the
ammonia level was normalized down to 60 mg/dl after 24 h
of 5-FU discontinuation, followed by complete recovery of the
patient’s mental status.
In this patient, we checked mRNA levels of three represen-
tative 5-FU metabolism-related genes including dihydro-
pyrimidine dehydrogenase (DPD), thymidine synthase (TS)
and thymidine phosphorylase (TP), using real-time PCR.
Heparinized blood was obtained from the patient before treat-
ment and at the second cycle of chemotherapy just after the
neurological attack had occurred. As a control, 16 patients
who received infusional 5-FU of the same dose and schedule
as the case patient were collected and blood sampling was
done before and after treatment. Total RNA of the peripheral
blood mononuclear cells was isolated using Trizol Reagent
(GibcoBRL, Grand Island, NY, USA). After confirming an
rRNA band on an agarose gel, 1.6 mg of RNA was reversed-
transcribed using a First Strand cDNA Synthesis kit (MBI
Fermentas, Lithuania).
Two microliters of cDNA was used for the real-time PCR
assay. The total volume of the reaction mixture was 20 ml,
containing HotstarTaq DNA polymerase, QuantiTect SYBR
Green PCR buffer, dNTP mix include dUTP, SYBR Green,
10 ml of QuantiTect SYBR Green PCR Kit including 2.5 mM
MgCl2 (QIAGEN, CA, USA), 2 ml of the cDNA and 20 pmol
of each primer (Proligo Singapore Pty Ltd, Singapore). PCR
was performed 1 cycle at 95 ml for 15 min and then for
35 cycles of amplification at; 95 ml for 20 s, 50 ml for 30 s,
72 ml for 45 s on a Rotor Gene 2072D real-time PCR machine
(Corbett Research, Australia). The amplified fluorescence
signal in each specimen was measured at the late extension
step of each cycle. In order to quantify each gene, we used
10-fold serial dilution of human genomic DNA (Promega,
Madison, WI, USA). The standard curve was drawn by plotting
the measured threshold cycle versus the arbitrary unit of
the copies/reaction according to the b-actin expression. The
threshold cycle (Ct) value was determined as the cycle number
at which the fluorescence exceeded the threshold value. The
following human specific primers were used: for DPD, 50-GTG
Table 1. Summary of chemotherapy schedule
1st cycle 2nd cycle 3rd cycle 4th cycle
BSA (m2) 1.48 1.55 1.64 1.64
5-FU (mg, 1000 mg/m2) 1480 1550 1640 1640
Cisplatin (mg, 70 mg/m2) 103 108 98* 98*
BSA, body surface area (m2).
*Dose of the cisplatin was reduced from 70 to 60 mg/m2 owing to encephalopa-
thy after the second cycle.
Table 2. Major laboratory findings of the patient during encephalopathy
Reference Cycle 2 Cycle 3 Cycle 4
PreTx D5* D6 PreTx D5 D6 PreTx D2* D6
NH3 (mg/dl) 0–64 58 354 75 63 120 64 60 555 60
AST/ALT (IU/l) 13–34/5–36 19/22 24/23 19/20 17/22 23/26 26/25 18/11 17/21 35/18
T. bil (mg/dl) 0.2–1.2 0.6 1.6 0.5 0.5 0.7 0.5 0.8 1.8 0.7
BUN (mg/dl) 5–25 20.6 23.2 20.0 17.2 15.2 15.9 18.0 17.4 21.0
Cr (mg/dl) 0.5–1.4 1.2 1.2 1.1 0.9 1.2 1.3 1.1 1.3 1.2
Na (mmol/l) 135–145 141 139 138 142 140 139 141 139 143
K (mmol/l) 3.5–5.5 4.3 4.9 4.2 4.2 3.8 4.1 4.3 4.2 4.5
AST, aspartate aminotransferase; ALT, alanine aminotransferase; BUN, blood urea nitrogen; Cr, creatinine.
*The sample was taken when neurotoxicity developed.
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AGA AGGACC TCA TAA AAT ATT GTC-30 (sense) and 50-
GAA TTG GAT GTT TAA ATA AAC ATT CAC CAA C-30
(antisense); for TP, 50-GGA TTC AAT GTC ATC CAG AG-30
(sense) and 50-CCT CCA CGA GTT TCT TAC TG-50
(antisense), and for TS, 50-TTT TTA AGG ATG TTG CCA
CT-30 (sense) and 50-GTG TTA CTC AGC TCC CTC AG-30
(antisense).
The total amount of RNA of DPD, TP and TS of the patient
normalized with b-actin were compared with those of control.
When pretreatment level of each value of control patients
was considered as 100%, the patient’s pre-treatment level
of DPD was within the control level, while those of TP and
TS were somewhat lower (69 and 67% of the control, respec-
tively). After 5-FU treatment, the patient’s DPD level was
markedly elevated up to 187% of the pre-treatment level.
The patient’s post-treatment levels of TP and TS were also
elevated up to 127% of initial level (Fig. 1).
DISCUSSION
The incidence of 5-FU neurotoxicity in patients undergoing
high-dose 5-FU chemotherapy is estimated to be 5.7% (5,6).
The risk factors are not well described, but it has been reported
that the combination of 5-FU and interferon a–2a increased
the incidence of neurotoxicity (7). The diagnostic criteria of
the 5-FU induced acute neurotoxicity includes: (i) develop-
ment of encephalopathy during or shortly after completion of
5-FU administration; (ii) exclusion of other metabolic factors
that may affect consciousness and mental functioning, such as
hypoglycemia, organ failure, electrolyte imbalance, sepsis
and central nervous system metastasis and (iii) exclusion of
an adverse effect by concomitant medications (1,8).
Although the biochemical basis for neurological toxicity
of the 5-FU is not fully understood, there have been at least
two distinct pathogenetic entities suggested for 5-FU-induced
encephalopathy (9). First is the DPD deficiency type. DPD
is the major enzyme to inactivate 5-FU, and its deficiency
results in the failure of 5-FU catabolism that leads to drug
accumulation. Approximately 85% of 5-FU is degraded by
DPD and this process produces ammonia as the end product.
In a population study, the prevalence of DPD deficiency,
defined as <95% distribution range of normal of DPD activity,
was reported to be 2.7% in cancer patients. Patients who have
DPD deficiency have shownmore severe and more generalized
forms of 5-FU-related toxicity besides neurotoxcitiy (10–12).
The second is 5-FU catabolite type. In this type, although
the major catabolic pathway of 5-FU remains intact, the rela-
tively high rate of 5-FU infusion results in a transient accu-
mulation of 5-FU catabolites in a short time period. Koenig
et al. proposed a hypothesis that following large dose admin-
istration, a large amount of fluoroacetate, the intermediate
product of 5-FU, directly inhibits the Kreb’s cycle and con-
sequently causes impairment in the ATP-dependent urea
cycle (13). This results in a transient hyperammonemia,
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Figure 1. Comparison of the changes of patient’s mRNA levels of 5-FU metabolism-related genes extracted from peripheral blood mononuclear cells before and
after the 5-FU treatment using real-time PCR. Control means 16 patients who received infusional 5-FU of the same dose and schedule as the case patient.
(DPD, dihydropyrimidine dehydrogenase; TP, thymidine phosphorylase; TS, thymidine synthetase).
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which could induce encephalopathy. Okeda et al. also sug-
gested that 5-FU metabolites, monofluoroacetic acid and
a-fluoro-b-alanine, could have a direct toxicity on myelin
itself (14). Although its mechanism remains to be further
elucidated, this form of neuropathy is milder than DPD defi-
ciency type. It is generally reversible and is also known not
to preclude a re-treatment with 5-FU at reduced dosages.
Most cases of 5-FU-related encephalopathy have been
reported to be associated with weekly high-dose infusion of
fluorouracil, which was enforced by high-dose folinic acid,
using 2200–2600 mg/m2/week of 5-FU, measuring 5-FU
dose intensity >1600 mg/m2/week. The patient received
5-FU with its actual dose intensity of 1170 mg/m2/week,
which is lower than weekly high-dose schedule. In our case,
the patient’s mental change emerged during 5-FU infusion
without remarkable predisposing factors: malnutrition, infec-
tion or hypotriglyceridemia. Although we did not perform
invasive study such as spinal tap, imaging study of the
brain properly ruled out infection, stroke, and leptomeningeal
seeding. There were no concomitant medications that could
have affected his mental status. Cisplatin and dexamethasone
can also cause encephalopathy, but ciplatin-related neuro-
toxicity has a feature of focal neurological deficit such as
seizure, ocular symptom and peripheral feature. In addition,
there has been no report that any of these agents caused mental
change accompanying hyperammonemia. Moreover, signifi-
cant toxicities that were related to chemotherapy other than
neurotoxicity were not noted with the patient in the whole
course of treatment. Thus, we suggest that the patient’s mental
change is attributed to 5-FU. We cannot, however, clearly
explain why neurotoxicity was not noticed in the first and
the third cycle, but some elevation of serum ammonia level
was also documented at the third cycle, implying that baseline
insufficiency in 5-FU catobolism persistently existed in the
patient, although it may not be cumulative.
We did not determine the patient’s enzymatic activity of
DPD. Instead, we examined its mRNA levels with fluorouracil
metabolism-related genes, TS and TP, from the peripheral
blood mononuclear cells. Several reports demonstrated signifi-
cant association between DPD enzyme activity and mRNA
levels (15,16). The level was compared with a control from
16 patients who were treated with the same regimen. The pre-
treatment level of DPD of the patient was in the control range,
and its level was elevated up to 187% after 5-FU treatment,
accompanying elevation of TS. The elevation of the latter after
5-FU administration was basically consistent with the previous
reports. Because DPD is the primary enzyme responsible
for metabolizing 5-FU, the induction of DPD as a catabolic
enzyme for 5-FU would be expected although direct evidence
remained to be established (17). It is worth pointing out that
the patient’s pre-treatment DPD level was not strikingly low
compared with other patients and that inducibility of DPD
with treatment was maintained. This suggests that there is
little chance of the patient having DPD deficiency, and the
transient stagnation of 5-FU catabolites would have played
a rather important role in the development of neurotoxicity.
The measurement of the level of 5-FU metabolites and DPD
genotyping could offer further information on its precise role
in the pathophysiology of encephalopathy.
Prognosis is good if diagnosis is established. Treatment
includes: immediate discontinuation of 5-FU along with sup-
portive care such as fluid supplement, lactulose enema and
correction of predisposing factors (18). It is, therefore, impor-
tant to recognize this condition at an early stage. In conclusion,
we report here that encephalopathy can develop even with the
lower dose of 5-FU. Despite its rarity, if a patient showed
abrupt mental change during or right after continuous infusion
of 5-FU, drug-induced encephalopathy should be considered
in differential diagnosis in order for precise diagnosis to be
made and proper management to be introduced.
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